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Synthesis, characterization and antimicrobial activity of zinc(II) 
ibuprofen complexes with nitrogen-based ligands
Hijazi Abu Ali‡, Suhad N. Omar‡, Mohanad D. Darawsheh and Hadeel Fares
department of Chemistry, Birzeit university, Birzeit, Palestine
ABSTRACT
Metal carboxylate complexes possess different carboxylate coordination 
modes, e.g. monodentate, bidentate, and bridging bidentate. Five Zn(II) 
complexes were prepared and characterized in order to examine their 
coordination modes in addition to their biological activity. The syntheses 
were started by preparation of [Zn(ibup)2(H2O)2] (1). Then, different 
nitrogen-donor ligands reacted with 1 to produce [Zn(ibup)2(2-ampy)2] (2), 
[Zn(ibup)(2-ammethylpy)] (3), [Zn(ibup)(2,2′-bipy)] (4), and [Zn2(ibup)4(2-
methylampy)2] (5) (ibup  =  ibuprofen, 2-ampy  =  2-aminopyridine, 
2-ammethylpy  =  2-aminomethylpyridine, 2,2′-bipy  =  2,2′-bipyridine, 
2-methylampy  =  2-(methylamino)pyridine). IR, 1H NMR, 13C{1H}-NMR and 
UV–vis spectroscopies were used for characterization. The crystal structures 
of 2 and 5 were determined by single-crystal X-ray diffraction. Investigation 
of in vitro antibacterial activities for the complexes against Gram-positive 
(Micrococcus luteus, Staphylococcus aureus and Bacillus subtilis) and Gram-
negative (Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis) 
bacteria were done using agar well-diffusion method. Complex 1 showed 
antibacterial activity against Gram-positive bacteria. Complexes 2 and 3 did 
not exhibit antibacterial activity. Complex 4 showed antibacterial activity and 
was chosen for further studies to determine the inhibition zone diameter for 
different concentrations and to set the minimum inhibitory concentration. 
The antibacterial activity against most of the bacteria was minimized as a 
result of the complexation of zinc ibuprofen with 2,2′-bipy in 4.
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1. Introduction
The average human body contains ca. 3 g of zinc, which makes it the second most abundant trace 
element in the body after iron [1–4]. Zinc is the only metal that appears in all enzyme classes [1, 4]. It is 
mainly distributed in the blood, kidney, liver and bone [5]. Studies have shown that Zn(II) has important 
antibacterial and antiviral effects [6], and high zinc ion concentrations may have some antibacterial 
properties [7]. In addition, zinc inhibits the growth of many bacteria, e.g., Escherichia coli, Streptococcus 
faecalis and some strains of soil bacteria [8].
Heterocyclic organic compounds enter the formulations of many vitamins and drugs, playing 
an important role in biological systems. The literature indicates that ligands/drugs become more 
bacteriostatic upon complexation with transition metals as compared to unchelated ones [9]. 
Antimicrobial activity of nonsteroidal anti-inflammatory drugs (NSAIDs) have been reported [9a]. 
The antimicrobial activity of these NSAIDs was enhanced when complexed with metals and other 
nitrogen-based ligands [9a]. Several metal complexes accelerate the drug action and the efficacy 
of the organic therapeutic agent; Co(II) complexes with the NSAID mefenamic acid as ligand have 
been investigated as potential anti-inflammatory agents [9b]. Several research groups also reported 
Cu(II) complexes of mefenamic acid, naproxen, diclofenac [9c], diflunisal [9d], and flufenamic acid 
[9e]. Co(II) complexes of naproxen [9f ] and tolfenamic acid [9g] and Mn(II) complexes of tolfenamic 
acid [9h] have also shown anti-inflammatory activity. Zinc complexes with bioactive ligands have 
pharmaceutical effects because they can catalyze many enzymatic processes in biological systems; 
zinc(II) aliphatic carboxylates (like valproic acid) [10, 11] and aromatic carboxylates (like naproxen) 
[12] have been synthesized and studied as antibacterial and anti-malarial and in other biological 
fields [8, 13].
Ibuprofen “ibupH” (figure 1) is a NSAID. There are many side effects associated with the clinical use 
of NSAIDs. Therefore, numerous studies were performed to reduce these side effects. One successful 
strategy was the use of d-block metal complexes of NSAIDs as therapeutic agents. This approach is 
based on the observation that some d-block metal ions, such as Cu(II) and Zn(II), can act as anti-inflam-
matory agents [14, 15]; or sometimes this interaction may lead to a better understanding of the metal 
ion antagonism [16]. For example, the Zn(II) complex of aspirin has a better therapeutic index (2.64 
times) than aspirin itself and has improved physicochemical characteristics. The Zn-aspirin complex is 
more effective in therapy and less ulcerogenic than either aspirin alone or a physical mixture of aspirin 
and ZnSO4 [17–19].
The coordination of transition metals, and especially d10 metal ions such as Cd(II) and Zn(II), with 
the anti-inflammatory carboxylate agents tolmentin, ibuprofen, and naproxen was studied to examine 
their binding mode [12, 20–25]. Cu(II) ibuprofen with 2,2′-bipyridine (2,2-bipy), 1,10-phenanthroline 
(1,10-phen), and 2,9-dmphenan were synthesized and characterized [26]. The antimicrobial activity of 
the copper(II) complex of the fluoroquinolone antibacterial drug N-propyl-norfloxacin (Hpr-norf ) in 
the presence of phenanthroline has been tested, revealing increased potency in comparison to free 
Hpr-norf (minimum inhibition concentration, MIC = 4–16 μg ml−1) [27].
O
OH
Figure 1. structure of ibuprofen.
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Typically, ibuprofen is produced industrially as a racemate. The compound contains a chiral center 
in the α-position of the propionate. Hence, it has two enantiomers, dextrorotatory (S), and the levoro-
tatory (R). The biological effects and metabolism for the two enantiomers are different and the S−(+)− 
ibuprofen was found to be the active form [26].
Nitrogen-based ligand derivatives, carboxylate derivatives, and the Zn(II) cation are of interest due 
to their potential activity against different types of bacteria. Hence, we combine the three derivatives 
in one complex to enhance their biological activity. In the present work, the synthesis, characterization 
and antibacterial activity of new zinc(II) ibuprofen containing complexes with 2-aminopyridine (2-ampy), 
2-aminomethylpyridine (2-ammethylpy), 2,2′-bipy and 2-(methylamino)pyridine) (2-methylampy) are 
described. The crystal structures of [Zn(ibup)2(2-ampy)2] (2) and [Zn2(ibup)4(2-methylampy)2] (5) are 
reported.
2. Results and discussion
2.1. Synthesis of zinc complexes
[Zn(ibup)2(H2O)2] (1) was prepared by mixing zinc chloride and sodium ibuprofen aqueous solutions 
in 1 : 2 M ratio. The desired product was obtained as a white solid (scheme 1), structure of 1 was pre-
viously determined [26]. Mixed-ligand zinc(II) complexes were prepared by adding the appropriate 
N-donor ligand to the water insoluble 1 (scheme 2). The physical properties of 1-5 are summarized 
in table S1.
2.2. Crystallographic study of 2
The atomic numbering scheme and atom connectivity for 2 are shown in figure 2. The asymmetric unit 
of 2 contains a Zn(II) cation, two ibuprofen ligands and two 2-ampy ligands.
Figure 2. the molecular structure of 2 showing the atom labeling scheme.
Table 1. selected bond lengths (Å) and angles (°) for 2.
bond distance (Å) bond angle (°) bond angle (°)
n(1)–Zn(1) 2.055(3) C(5)–n(1)–Zn(1) 114.6(3) C(11)–o(1)–Zn(1) 119.1(2)
n(3)–Zn(1) 2.043(3) C(1)–n(1)–Zn(1) 126.6(3) o(3)–Zn(1)–o(1) 123.29(12)
o(1)–Zn(1) 1.920(2) o(3)–Zn(1)–n(1) 105.06(13) o(3)–Zn(1)–n(3) 110.49(12)
o(3)–Zn(1) 1.907(3) o(1)–Zn(1)–n(1) 110.01(13) o(1)–Zn(1)–n(3) 106.53(10)
    n(3)–Zn(1)–n(1) 98.75(11)    
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Zn(II) is surrounded by two monodentate ibuprofen ligands with O–Zn coordination distances of 
1.920(2) Å and 1.907(3) Å, which are a little shorter than similar reported distances [28, 29]. The 2-ampy 
ligands with distances involving pyridyl nitrogen and Zn being 2.055(3) Å and 2.043(3) Å are similar 
to previously reported distances (2.048 Å in average) [28, 29]. Selected bond distances and angles are 
tabulated in table 1.
Zn(II) has a distorted tetrahedral geometry. The deviation from regular tetrahedral is observed 
from binding angles O3–Zn1–O1 = 123.29(12)°, O3–Zn1–N3 = 110.49(12)°, O1–Zn1-N3 = 106.53(10)°, 
O3–Zn1–N1 = 105.06(13)°, O1–Zn1–N1 = 110.01(13)° and N3–Zn–N1 = 98.75(11)°. Intramolecular and 
intermolecular hydrogen bonds are shown in table S2. The first two bonds belong to the former while 
the last two bonds belong to the latter type.
The Zn–O distances for 2 are 1.84–2.33 Å, typical of monodentate acetate complexes [30]. The average 
C–O bond distance of coordinated oxygen is 1.273 Å, while the average of non-coordinated C–O oxygen 
is 1.212 Å. The difference in bond distances between the coordinated and non-coordinated C–O are 
considered an indication of non-delocalization of ibuprofen due to monodentate coordination. The aver-
age O–C–O bond angle in 2 is 123.8° as expected for monodentate carboxylate coordination [10–12].
Scheme 1. synthesis of 1.
Scheme 2. synthesis and the proposed structures of 2–5 (*: proposed structure).D
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2.3. Crystallographic study of 5
The atom numbering scheme and connectivity for 5 are shown in figure 3. The structure consists of 
centrosymmetric binuclear Zn units, with four ibuprofen bridging bidentate carboxylate residues. each 
Zn(II) has a square pyramidal coordination geometry with the apex provided by axial coordination of 
2-methylampy. Selected bond distances and angles are tabulated in table 2.
The Zn(1)⋯Zn(1)#1 distance in 5 is 3.0073(7) Å and lies within the average distance for four-co-
ordinate binuclear Zn clusters, [2.9–3.0 Å] [31]. The corresponding Zn⋯Zn distance observed in 
[Zn2(valp)4(quin)2] is [2.9481(3) Å] [10]; thus, the Zn⋯Zn distance in 5 is large enough to conclude no 
direct Zn–Zn bonding.
The O–Zn average distance is 2.037(5) Å, in accord with average distances in similar binuclear 
zinc mixed ligand complexes (i.e. [Zn2(valp)4(quin)2] 2.046(0) Å [10], [Zn2(indo)4(Py)2], 2.039(3) Å and 
[Zn2(indo)4(DMA)2], 2.042(2) Å [32]). The C1–O1, C1–O2 and C14–O3, C14–O4 distances are 1.254(4) Å, 
1.250(4) Å and 1.235(4) Å, 1.246(4) Å, respectively, as expected for carboxylates in bridging coordination. 
The values are close to each other and similar to the corresponding zinc valproate complex (1.253 Å) 
in bridging coordination mode [10].
The C–O–Zn average angle in 5 is 128.3°, larger than the corresponding metal carboxylates in bridg-
ing coordination (i.e. rhodium valproate complexes [118.8°] [33]), which supports the absence of direct 
Zn⋯Zn bonding.
Figure 3. the molecular structure of 5 showing the atom labeling scheme.
Table 2. selected bond lengths [Å] and angles [°] for 5.
bond distance (Å) bond angle (°)
n(1)–Zn(1) 2.030(3) o(2)#1–Zn(1)–o(3) 87.59(11)
o(2)–Zn(1)#1 2.017(2) C(14)–o(3)–Zn(1) 132.1(2)
o(4)–Zn(1)#1 2.052(2) C(14)–o(4)–Zn(1)#1 124.6(2)
Zn(1)–o(2)#1 2.017(2) o(2)#1–Zn(1)–n(1) 99.91(11)
Zn(1)–o(4)#1 2.052(2) o(1)–Zn(1)–n(1) 102.44(11)
Zn(1)⋯Zn(1)#1 3.0073(7) o(2)#1–Zn(1)–Zn(1)#1 75.99(7)
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2.4. Infrared and UV–vis spectra
Infrared spectral data of 1–5 from 400 to 4000 cm−1 as Kbr pellets are summarized in tables S3 and S4. In 
metal carboxylate complexes, the major characteristics of IR spectra are frequencies of the antisymmetric 
(νas(CO2)) and symmetric (νs(CO2)) stretching vibrations of the carboxylate and the difference between 
them ∆ν(CO2). The frequencies of these bands depend upon the coordination mode of the carboxylate. 
Monodentate binding of the carboxylate group exhibits ∆ν(CO2) values much higher than the ionic form. 
Chelating (bidentate) binding of the carboxylate group exhibits ∆ν(CO2) values significantly lower than 
the ionic form. The ∆ν(CO2) values for bridging coordination of the carboxylate are higher than those 
of chelating mode and close to the ionic values [34], i.e. ∆ν(CO2)monodentate >> ∆ν(CO2)ionic~∆ν(CO2)bridg-
ing > ∆ν(CO2)chelating. The antisymmetric stretching νas(CO2), the symmetric stretching νs(CO2) and the 
difference between these two values of ibuprofen carboxylate in 1–5 and those of sodium ibuprofen 
are shown in tables S3 and S4.
In 1, νas(CO2) is at 1545 cm
−1 and νs(CO2) at 1414 cm
−1, and ∆ν(CO2) = 131 cm
−1 which is lower than 
that of sodium ibuprofenate (∆ν(CO2)Na(ibup) = 150 cm
−1) gives an indication that the coordination mode 
of ibuprofen in 1 is chelating bidentate to form [Zn(ibup)2]. Dendrinou-Samara et al. synthesized 
[Zn(ibup)2(H2O)2] using the same procedure but used methanol/water as solvent; for the complex, 
νas(CO2) occurs at 1605 cm
−1 and νs(CO2) at 1390 cm
−1, ∆ν(CO2) = 215 cm
−1, and they suggest mono-
dentate coordination [16].
Complexes 2 and 3 exhibit νas(CO2) at 1624 and 1605 cm
−1, νs(CO2) occurs at 1352 and 1361 cm
−1, 
respectively, and the ∆ν(CO2) are 272 and 244 cm
−1, respectively, higher than ∆ν(CO2)Na(ibup) = 150 cm
−1, 
which supports monodentate coordination of the ibuprofen carboxylates. This is confirmed by the X-ray 
structure of 2. As expected for 2, two absorption frequencies at 3339 cm−1 and 3225 cm−1 have been 
assigned to 1˚−NH2. The corresponding N–H peak of 2 is lowered by 108 cm
−1 due to complexation 
through the pyridine nitrogen. The difference in NH2 stretching for 2 (νas(N–H) − νs(N–H)) is 114 cm
−1, 
while in free 2-ampy it is 262 cm−1. This indicates a hydrogen-bond in 2 [35], which is confirmed by the 
crystal structure of 2.
Complexation of NH2 will cause a larger shift for the two NH2 peaks [35]. 2-Aminomethylpy in 3 
binds to zinc through pyridine nitrogen and the amino group appears to be in chelating bidentate 
coordination as supported by the presence of a peak at 3288 cm−1 [36-39]. In contrast, two peaks are 
at 3364 and 3289 cm−1 for free 2-aminomethylpy. Metal complexes of 2-aminomethylpy that exhibit 
strong hydrogen bonding between the amine nitrogens and the carboxylate oxygens show one broad 
ν(NH2) peak [40]. In addition, 3 shows Zn–NH2 stretching frequency at 448 cm
−1 [41].
For 4, νas(CO2) is at 1624 cm
−1 and νs(CO2) is at 1373 cm
−1. The high value of ∆ν(CO2) = 251 cm
−1 is 
an indication of monodentate coordination of ibuprofen carboxylate since the separation frequency 
is higher than that of sodium ibuprofen (∆ν(CO2) = 150 cm
−1). This value is in agreement with other 
monodentate zinc carboxylate complexes [42]. Infrared spectra of metal complexes of 2,2′-bipy have 
been studied extensively [42]. In general, bands at high frequency are not metal-sensitive since they 
originate from the heterocyclic or aromatic rings of the ligand. Thus, the main interest has focused on 
the low frequency region, where M–N and other metal sensitive vibrations appear. However, it is difficult 
Table 3. Binding modes of 1–5 depending on 13C{1h}-nmr data.
*δ(Co2)calculated = (δ 
13C(Co2) – δ 
13C(Ch3)).
Compound δ 13C(CH3) (ppm) δ 
13C(CO2) (ppm) δ 
13C(CO2)cal.* (ppm) binding mode
h(ibup) 22.47 181.35 158.88 –
na(ibup) 22.80 201.00 178.20 ionic
1 22.67 189.46 166.79 Chelating bidentate
2 22.66 179.82 157.16 monodentate
3 22.68 179.46 156.78 monodentate
4 22.65 150.01 127.36 monodentate
5 22.45 181.93 159.48 Bridging bidentate
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to assign ν(M–N) empirically since several ligand vibrations also appear in the same frequency region 
[34]. Peaks at 3127, 3054, 1512 and 761 cm−1 are characteristic of 2,2′-bipy present in 4 [42].
For 5, νas(CO2) is at 1624 cm
−1 and νs(COO
−) is at 1460 cm−1. The value of ∆ν(CO2) = 164 cm
−1 is close 
to the value of sodium ibuprofen (∆ν(CO2) = 150 cm
−1). It is clear from the X-ray crystal structure of 5 
(figure 3) that the coordination mode is bridging bidentate as indicated from IR data and ∆ν(CO2) value.
All the complexes are white, with a d10 Zn(II). From the results tabulated in table S5, no ligand-
to-metal charge-transfer bands are observed. The bands are assigned to intraligand transitions; the 
spectra of the complexes are similar to those of nitrogen-donor ligands with very small shifts caused 
by zinc coordination.
2.5. 1H- and 13C{1H}-NMR
1H and 13C{1H}-NMR spectral data of ibuprofen and 1–5 are listed in tables S6-S10. Comparison of the 
1H-NMR spectra of 1 and ibuprofen showed the absence of the O-H resonance in addition to slight 
upfield shift for most resonances. In the 13C{1H}-NMR spectrum of 1, the C=O resonance was shifted 
downfield form 181.35 ppm to 189.46 ppm; this deshielding indicates donation of electrons from the 
ibuprofen carboxylate to Zn(II). Downfield shift for the resonance of carbon adjacent to carbonyl was 
also observed, i.e. CH 45.08 ppm to 45.32 ppm and CH3 ppm 18.15 to 19.41 ppm which prove the inter-
action of the carboxyl part of ibuprofen to Zn(II). For 2–5, slight shifts in the 1H- and 13C NMR spectra 
were noticed upon complexation. The integration of the 1H-NMR signals is used to determine the 
coordination number of the complexes. The ratio between the nitrogen-based ligands and ibuprofen 
was 1 : 1 in 2 and 3, while in 4 and 5, the ratio was 1 : 2.
The 13C{1H}-NMR chemical shifts of the carboxylate groups depend on the coordination number and the 
coordination mode of the complexed metal [43]. To determine the carboxylate binding mode, it is necessary 
to use a reference in the spectra. The terminal methyl group of ibuprofen can be used as a reference which 
is less affected by complexation. The 13C{1H}-NMR chemical shifts of carbonyl group of different modes 
are in the following order [43]: δ13C(CO2)ionic > δ
13C(CO2)chelating > δ
13C(CO2)bridging > δ
13C(CO2
−)monodentate. 
Table 4. In vitro antibacterial activity data of 1–4. inhibition zone diameter (iZd) in mm, all micro-organisms were resistant to dmso. 
the data stated as average ± standard deviation (n = 3), the concentration was 30 mg 5 ml−1 in dmso (6 g l−1).
“–” indicates zero inhibition.
Compound
B. subtilis M. luteus S. aureus E. coli K. pneumoniae P. mirabilis
G+ G+ G+ G− G− G−
ZnCl2 – – – – – –
na(ibup) – – – – – –
1 10.3 ± 0.6 11 ± 1 12 ± 3 – – –
2 – – – – – –
3 – – – – – –
4 12 ± 1 13 ± 3 15 ± 2 14.1 ± 0.1 11.3 ± 0.6 14.1 ± 0.3
erythromycin 36.0 37.0 38.0 18.0 21.0 17.0
Gentamycin 25.0 32.0 27.0 28.0 31.0 28.0
Table 5. antibacterial activity data (inhibition zone diameter (iZd) in mm) for 4 and 2,2′-bipy.
Compound Concentration (g/l DMSO)
B. subtilis M. luteus S. aureus E. coli K. pneumoniae
P. mira-
bilis
G+ G+ G+ G− G− G−
4 6 12.3 13.0 15.0 14.1 11.3 14.1
  3 9 8 13 11 8 12
  1.5 – – 9 8 7 11
2,2′-bipy 6 21 28 12 27 27 22
  3 11 21 10 26 21 19
  1.5 – 15 9 14 15 16
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Therefore, the 13C{1H}-NMR chemical shifts of the carboxylate group were calculated and are tabulated 
in table 3.
Complexes 2 and 5 show monodentate and bridging bidentate coordination, respectively, and 
exhibit carboxylate group chemical shift (δ(CO2)cal.) values of 157.16 and 159.48 ppm, respectively. In 
complexes with a δ(CO2)cal value close to or lower than 157.16 ppm, the carboxylate group was consid-
ered as having monodentate coordination. based on this, in 3 and 4 the ibuprofen carboxylate groups 
are monodentate which agrees with the results obtained from IR spectroscopy. The crystal structure 
and δ(CO2)cal are compatible since, as discussed in the crystal structure of 5, it is clear that ibuprofen car-
boxylate groups bind in bidentate bridging coordination. Complex 1 has the highest value of δ(CO2)cal. 
Therefore, this enforces the results of IR spectroscopy that suggest chelating bidentate mode.
2.6. Antibacterial activity
before we performed the biological measurements, the solution stability of 1–4 was checked peri-
odically by 1H- and 13C NMR spectroscopy in chloroform and DMSO solvents. No major changes were 
observed between the measurements. In addition, the complexes were crystallized by solvent evapo-
ration which took several days and the NMR measurements were repeated to give the same physical 
properties of the compounds.
Three Gram-positive bacteria (Micrococcus luteus, Staphylococcus aureus and Bacillus subtilis) and 
three Gram-negative bacteria (E. coli, Klebsiella pneumonia and Proteus mirabilis) were used to test the 
antibacterial activity of the compounds. The results were obtained by the well-diffusion method using 
a 30 mg 5 ml−1 concentration (in DMSO) with a volume of 50 μl per well. The values of the antibacterial 
activity are the average of three trials and are stated as average ± standard error. The results are tab-
ulated in table 4 using DMSO as a negative control while erythromycin and gentamycin were used as 
positive controls. The sodium ibuprofen and Zn(II) (as ZnCl2) did not show antibacterial activity against 
any of the tested microorganisms, and erythromycin and gentamycin as positive controls showed high 
antibacterial activity against all tested bacterial species with inhibition zone diameter (IZD) of 17–43 
and 23–33 mm, respectively.
Complex 1 exhibited antibacterial activity only against Gram-positive bacteria with IZD of 
10–12 mm. Complexes 2 and 3 did not exhibit activity against Gram-positive or Gram-negative 
bacteria. The efficiency of 4 against all tested micro-organisms is good with IZD 11-15 mm. Complex 
4 was chosen for further studies because of its higher IZD values. Thus, 4 has been studied with 
its parent nitrogen-donor ligand 2,2′-bipy against all tested Gram-positive and Gram-negative 
bacteria; the aim of this step was to determine the effect of the complexation on antibacterial 
activity. Dilutions of the complex and 2,2′-bipy were prepared in DMSO using the same procedure; 
the complex and the parent ligand were tested in the same plate to reserve the same conditions 
for both. All antibacterial results are listed in table 5. It is clear from the results that the complex-
ation of zinc ibuprofen with 2,2′-bipy in 4 has decreased the antibacterial activity against most 
tested bacteria. The lowest concentration that inhibits bacterial growth is the minimum inhibition 
concentration (MIC). The MIC values for 4 were compared side by side with those of 2,2′-bipy 
(table 6). The MIC values for 4 are close to those of free 2,2′-bipy, which indicate a weak effect of 
complexation on antibacterial activity.
Table 6. minimum inhibition concentrations (miC, in μg/ml) of 4 and 2,2′-bipy.
Compound
B. subtilis M. luteus S. aureus E. coli K. pneumoniae P. mirabilis
G+ G+ G+ G− G− G−
4 3000 3000 1500 1500 1500 1500
2,2′-bipy 3000 188 1500 1500 1500 1500
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3. Conclusion
The synthesis and characterization of four new Zn(II) complexes with the NSAID ibuprofen in the pres-
ence of N-donor heterocyclic ligands 2-ampy, 2-ammethylpy, 2,2′-bipy and 2-methylampy have been 
achieved. 1H- and 13C{1H}-NMR, IR and UV–vis spectroscopies were used to study and characterize the 
new complexes in addition to X-ray diffraction of 2 and 5. The results revealed distorted tetrahedral 
geometry of Zn(II) in 2 with two monodentate ibuprofen ligands and two 2-ampy ligands. The structure 
of 5 consists of centrosymmetric binuclear Zn units, with four ibuprofen bridging bidentate ligands. 
each Zn(II) has a square pyramidal coordination geometry with the apex provided by axial coordination 
of 2-methylampy. Complexes 3 and 4 are proposed to have monodentate coordination of ibuprofen 
carboxylate as predicted by NMR, IR and UV-vis results. Complex 4 showed antibacterial activity against 
G-(+) and G-(-) bacteria, whereas the complexation of 2,2′-bipy in 4 decreased the antibacterial activity 
compared with that of free 2,2′-bipy. Complex 5 did not show any antibacterial activity against G−(+) 
and G−(-) bacteria.
4. Experimental
4.1. Starting materials
Zinc(II) chloride was purchased from Merck, sodium ibuprofen from Sigma and 2-aminopyridine, 2-ami-
nomethylpyridine and 2,2′-bipyridine were purchased from Aldrich. All solvents were of analytical rea-
gent grade and purchased from commercial sources. M. luteus, S. aureus, B. subtilis, E. coli, K. pneumonia, 
and P. mirabilis were obtained from the biology and biochemistry Department at birzeit University.
4.2. Synthesis
All Zn(II) complexes were synthesized at room temperature in ambient conditions.
4.2.1. Synthesis of the precursor [Zn(ibup)2(H2O)2] (1)
Ibuprofen (6.18 g, 0.03 mol) was dissolved in a solution of sodium hydroxide (1.20 g, 0.03 mol) in 100 ml 
water. To this solution, a solution of zinc chloride (2.05 g, 0.015 mol) in 30 ml of water was slowly added 
with stirring in molar ratio 2 : 1. The mixture was allowed to stir for 1 h, and the precipitate formed was 
collected, washed with cold water and dried in vacuum.
[Zn(ibup)2(H2O)2] (1): ~90% (6.50 g) yield, m.p. = 86.8–94.3 °C. 
1H NMR (CDCl3): δ (ppm) 0.89 (d, 6H, CH3, 
3JH–H = 6.6 Hz), 1.36 (d, 3H, CH3, 
3JH–H = 6.9 Hz), 1.82 (m, 1H, CH), 2.42 (d, 2H, CH2, 
3JH–H = 7.2 Hz), 3.62 (q, 
1H, CH, 3JH–H = 7.2 Hz), 7.03 (d, 2H, CH, 
3JH–H = 8.1 Hz), 7.15 (d, 2H, CH, 
3JH–H = 8.1 Hz). 
13C{1H}-NMR (CDCl3): 
δ (ppm) 19.41 (CH3), 22.67 (CH3), 30.42 (CH), 45.32 (CH), 47.24 (CH2), 127.44 (CH), 129.41 (CH), 138.65 (C), 
140.51 (C), 189.46 (C=O). IR (cm−1, Kbr): 3090 w, 2953 s, 2925 s, 2867 m, 1706 w, 1544 vs 1512 m, 1414 vs 
1366 m, 1290 m, 1121 w, 1070 m, 848 m, 786 w, 740 w, 607 w, 548 w, 430 w. UV–vis (etOH, λ (nm)): 315.
4.2.2. Synthesis of [Zn(ibup)2(2-ampy)2] (2)
2-Aminopyridine (0.56 g, 5.95 mmol) was dissolved in acetone and gradually added to stirred acetone 
solution of 1 (1.43 g, 1.50 mmol). The solution was stirred for 3 h, and then evaporated to dryness under 
vacuum to get a solid residue. The solid product was washed with ether and allowed to dry in air. Suitable 
crystals for X-ray structural analysis were obtained by recrystallization from acetone.
[Zn(ibup)2(2-ampy)2] (2): ~64% (1.28 g) yield. m.p. = 151.2–152.7 °`C. 
1H NMR (CDCl3): δ (ppm) 0.84 
(d,6H, CH3, 
3JH–H = 6.6 Hz), 1.32 (d, 3H, CH3, 
3JH–H = 6.9 Hz), 1.79 (m, 1H, CH(ibup)), 2.38 (d, 2H, CH2, 
3JH–
H = 6.9 Hz), 3.54 (q, 1H, CH(ibup), 
3JH–H = 6.9 Hz), 6.45 (bs, 2H, NH2), 6.53 (m, 2H, CH), 7.02 (d, 2H, CH(ibup), 
3JH–
H = 7.5 Hz), 7.19 (d, 2H, CH(ibup), 
3JH–H = 7.8 Hz) 7.42 (t, 1H, CH, 
3JH–H = 9.0 Hz), 7.74 (d, 1H, CH, 
3JH–H = 4.8 Hz). 
13C{1H}-NMR (CDCl3): δ (ppm) 20.33 (CH3), 22.66 (CH3), 30.11 (CH(ibup)), 44.79 (CH(ibup)), 46.53 (CH2), 110.09 
(CH), 112.15 (CH), 127.63 (CH(ibup)), 129.02 (CH(ibup)), 138.83 (CH), 139.07 (C(ibup)), 141.23 (C(ibup)), 147.04 
(CH), 160.06 (C–NH2), 179.82 (C = O). IR (Kbr, cm
−1): 3370 s, 3339 s, 3225 s, 3030 vw, 2954 s, 2925 m, 
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2866 m, 1640 s, 1624 vs 1566 s, 1502 vs 1454 s, 1378 s, 1352 s, 1272 s, 1165 m, 1066 m, 1009 m, 885 w, 
850 s, 769 s, 740 m, 725 w, 633 w, 543 w, 457 m, 414 w. UV–vis (DMSO, λ (nm)): 301.
4.2.3. Synthesis of [Zn(ibup)2(2-ammethylpy)] (3)
The same procedure was followed as for 2 except with 2-aminomethylpyridine (0.15  ml, 0.14  g, 
1.27 mmol) and 1 (0.30 g, 0.32 mmol).
[Zn(ibup)2(2-ammethylpy)] (3): ~62% (0.27 g) yield. m.p. = 154.8–156.9 °C. 
1H NMR (CDCl3): δ (ppm) 
0.85 (d, 6H, CH3, 
3JH–H = 5.7 Hz), 1.23 (d, 3H, CH3, 
3JH–H = 6.3 Hz), 1.77 (m, 1H, CH(ibup)), 2.34 (d, 2H, CH2(ibup), 
3JH–H = 6.3 Hz), 3.42 (q, 1H, CH(ibup), 
3JH–H = 7.2 Hz), 3.53 (bs, 2H, NH2), 3.94 (bd, 2H, CH2, 
3JH–H = 5.4 Hz), 
6.96 (d, 2H, CH(ibup), 
3JH–H = 7.5 Hz), 7.10 (d, 2H, CH(ibup), 
3JH–H = 9.6 Hz), 7.35 (t, 1H, CH, 
3JH–H = 5.1 Hz), 7.46 
(d, 1H, CH, 3JH–H = 7.5 Hz), 7.89 (m, 1H, CH), 8.42 (d, 1H, CH, 
3JH–H = 4.8 Hz). 
13C{1H}-NMR (CDCl3): δ (ppm) 
20.59 (CH3), 22.68 (CH3), 30.13 (CH(ibup)), 44.76 (CH(ibup)), 44.88 (CH2(ibup)), 46.99 (CH2), 122.56 (CH), 123.18 
(CH), 127.58 (CH(ibup)), 128.83 (CH(ibup)), 136.39 (CH), 138.75 (C(ibup)), 141.91 (C(ibup)), 148.11 (CH), 161.07 (C), 
179.46 (C = O). IR (Kbr, cm−1): 3288 m, 3125 w, 2955 s, 2924 m, 2868 m, 1672 s, 1605 vs 1546 w, 1508 s, 
1487 vs 1455 s, 1435 m, 1387 w, 1361 m, 1287 s, 1254 s, 1220 m, 1129 m, 1097s, 1064 s, 1040 m, 1016 m, 
877 m, 850 s, 787 m, 759 w, 733 m, 708 s, 673 m, 640 m, 593 m, 491 w, 463 m, 448 s, 441 w. UV–vis (etOH, 
λ (nm)): 315. eSI (M+-18 = 675.23).
4.2.4. Synthesis of [Zn(ibup)2(2,2′-bipy)] (4)
The same procedure was followed as for 2 except with 2,2′-bipyridine (0.30 g, 1.92 mmol) and 1 (0.52 g, 
0.55 mmol).
[Zn(ibup)2(2,2′-bipy)] (4): ~33% (0.23 g) yield. m.p. = 143.6–146.3 °C. 
1H NMR (CDCl3): δ (ppm) 0.86 
(d, 6H, CH3, 
3JH–H = 6.6 Hz), 1.44 (d, 3H, CH3, 
3JH–H = 6.9 Hz), 1.78 (m, 1H, CH(ibup), 
3JH–H = 6.6 Hz), 2.38 (d, 
2H, CH2, 
3JH–H = 7.2 Hz), 3.71 (q, 1H, CH(ibup), 
3JH–H = 7.2 Hz), 6.94 (d, 2H, CH(ibup), 
3JH–H = 9.0 Hz), 7.19 (d, 2H, 
CH(ibup), 
3JH–H = 9.0 Hz), 7.66 (dd, 1H, CH, 
3JH–H = 8.4 Hz), 7.91 (bs, 1H, CH), 8.34 (d, 1H, CH, 
3JH–H = 9.0 Hz), 
9.02 (d, 1H, CH, 3JH–H = 8.1 Hz). 
13C{1H}-NMR (CDCl3): δ (ppm) 19.82 (CH3), 22.65 (CH3), 30.44 (CH(ibup)), 45.31 
(CH(ibup)), 46.38 (CH2), 124.76 (CH), 126.68 (CH), 127.30 (CH(ibup)), 128.57 (CH(ibup)), 128.79 (CH), 138.43 
(C(ibup)), 139.19 (C(ibup)), 140.76 (CH), 149.67 (C), 183.41 (C = O). IR (Kbr, cm
−1): 3127 m, 3054 w, 2961 s, 
2864 m, 1624 s, 1512 m, 1456 m, 1373 s, 1275 s, 1159 m, 1001 m, 881 m, 848 m, 800 w, 761 m, 677 m, 
593 m, 443 m. UV–vis (etOH, λ (nm)): 308. eSI (M+-18 = 629.11).
4.2.5. Synthesis of [Zn2(ibup)4(2-methylampy)2] (5)
The same procedure was followed as for 2 except with 2-(methylamino)pyridine (0.30  ml, 0.28  g, 
2.54 mmol) and 1 (0.60 g, 0.64 mmol).
[Zn2(ibup)4(2-methylampy)2] (5): ~75% (0.65 g) yield. m.p. = 135.0–137.0 °C. 
1H NMR (CDCl3): δ (ppm) 
0.91 (d, 6H, CH3, 
3JH–H = 6.3 Hz), 1.39 (d, 3H, CH3, 
3JH–H = 6.9 Hz), 1.84 (m, 1H, CH(ibup), 
3JH–H = 6.6 Hz), 2.43 (d, 
3H, CH3, 
3JH–H = 6.9 Hz), 2.53 (s, 3H, NCH3), 3.54 (q, 1H, CH(ibup), 
3JH–H = 6.9 Hz), 6.37 (d, 2H, CH, 
3JH–H = 9.0 Hz), 
6.42 (t, 1H, CH, 3JH–H = 6.0  Hz), 7.02 (d, 2H, CH(ibup), 
3JH–H = 7.8  Hz), 7.20 (d, 2H, CH(ibup), 
3JH–H = 7.8  Hz), 
7.50 (t, 1H, CH, 3JH–H = 9.0 Hz), 7.72 (d, 1H, CH, 
3JH–H = 5.1 Hz). 
13C{1H}-NMR (CDCl3): δ (ppm) 19.77 (CH3), 
22.45 (CH3), 28.94 (NHCH3), 30.24 (CH(ibup)), 45.12 (CH(ibup)), 47.02 (CH2), 106.40 (CH), 111.76 (CH), 127.40 
(CH(ibup)), 128.88 (CH(ibup)), 139.34 (CH), 140.10 (C(ibup)), 140.35 (C(ibup)), 146.94 (CH), 159.11 (C–NH), 181.93 
(C=O). IR (Kbr, cm−1): 3371 s, 3171 vw, 2959 s, 2867 s, 1647 s, 1624 vs 1538 m, 1514 m, 1460 s, 1414 s, 
1286 s, 1169 s, 1074 m, 1012 m, 920 m, 888 m, 843 s, 790 m, 761 s, 640 m, 595 s, 496 m, 494 w. UV–vis 
(DMSO, λ (nm)): 303.
4.3. Physical measurements
Infrared (IR) spectra were recorded from 200 to 4000 cm−1 (Kbr) on a Varian 600 FT-IR spectrometer. 
UV–Vis spectra were recorded using a Hewlett Packard 8453 photodiode array spectrophotometer from 
200 to 800 nm using DMSO as solvent. NMR spectra were recorded on a Varian Unity spectrometer 
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operating at 300 MHz for 1H NMR spectra and 75 MHz for the 13C{1H}-NMR spectra (CDCl3). Melting 
points were determined in capillary tubes with eZ-Melt apparatus without any correction.
4.4. X-ray crystallography
X-ray intensity data of 2 and 5 were carried out at room temperature on a bruker SMART APeX CCD 
X-ray diffractometer system (graphite–monochromated Mo Kα radiation λ = 0.71073 Å) using SMART 
software package [44]. The data were reduced and integrated by the SAINT program package [45]. 
The structure was solved and reﬁned by the SHelXTl software package [46]. Hydrogens were located 
geometrically and treated with a riding model. Crystal data and details of the data collection and 
refinement are summarized in table 7.
4.5. Antibacterial activity
Three Gram-positive bacteria (M. luteus, S. aureus, and B. subtilis) and three Gram-negative bacteria (E. 
coli, K. pneumonia, and P. mirabilis) were used to test antibacterial activity. The tests were carried out 
using the agar-well diffusion method [47].
The wells (6 mm in diameter) were dug in the media with the help of a sterile glassy borer. Single 
bacterial colonies were dissolved in sterile saline until the suspended cells reached the turbidity of 
McFarland 0.5 Standard. The bacterial inocula were spread on the surface of the Muller Hinton nutrient 
agar with help of a sterile cotton swab. 50 μl of the test samples (30 mg 5 ml−1 DMSO “6 g l−1”) were 
introduced in the respective wells. Another well was supplemented with DMSO for negative control. 
The plates were incubated immediately at 37 °C for 24 h. The antibacterial activity was determined by 
measuring the diameter of complete growth inhibition zone in millimeters (mm). The results are the 
average of three trials and they are stated as average ± standard deviation.
Table 7. Crystal data and structure refinement of 2 and 5.
aR1 = Σ||F₀|-|Fc|| / Σ F₀, wR2 = {Σ[w(F₀
2 – Fc
2)2]/ Σ[w(F₀
2)2}1/2.
  2 5
empirical formula C36h46n4o4Zn C64h84n4o8Zn2
formula weight 664.14 1168.09
temperature 295(1) K 293(1) K
Wavelength 0.71073 Å 0.71073 Å
Crystal system triclinic triclinic
space group P-1 P-1
unit cell dimensions a = 11.166(1) Å α = 70.797(2)° a = 10.655(1) Å α = 97.146(2)°
b = 11.232(1) Å β = 81.611(2)° b = 11.095(1) Å β = 108.123(2)°
c = 16.251(2) Å γ = 75.996(2)° c = 15.496(2) Å γ = 108.074(2)°
Volume 1862.6(3) Å3 1604.9(3) Å3
Z 2 1
density (calculated) 1.184 mg m−3 1.209 mg m−3
absorption coefficient 0.699 mm−1 0.800 mm−1
F(0 0 0) 704 620
Crystal size 0.33 × 0.25 × 0.07 mm3 0.34 × 0.23 × 0.12 mm3
theta range for data collection 1.88 to 27.99° 2.85 to 27.00°
index ranges −14 ≤ h ≤ 14, −14 ≤ k ≤ 14, −21 ≤ l ≤ 20 −13 ≤ h ≤ 13, −14 ≤ k ≤ 14, −19 ≤ l ≤ 19
reflections collected 20,963 17,459
independent reflections 8572 [R(int) = 0.0350] 6880 [R(int) = 0.0279]
Completeness to theta = 27.00° 95.40% 98.0%
absorption correction none none
refinement method full-matrix least-squares on F2 full-matrix least-squares on F2
data/restraints/parameters 8572/2/409 6880/5/362
Goodness-of-fit on F2 0.964 1.069
final R indices [I>2σ(I)] R1 = 0.0629, wR2 = 0.1663 R1 = 0.0628, wR2 = 0.1626
R indices (all data) R1 = 0.1191, wR2 = 0.1978 R1 = 0.0751, wR2 = 0.1706
largest diff. peak and hole 0.860 and −0.279 e.Å−3 0.776 and −0.364 e.Å−3
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Complex 4 was selected for further antibacterial studies. Serial dilutions in DMSO of this complex and 
2,2′-bipy were prepared. The diluted solutions were tested in similarly prepared plates using the same 
procedure. The inhibition zone diameter (IZD) at 30, 15, and 7.5 mg 5 ml−1 DMSO and the minimum 
inhibition concentration (MIC) were determined for 4 and 2,2′-bipy.
Supplementary material
CCDC 1026551 and CCDC 1432996 contain the supplementary crystallographic data for 2 and 5. These data can be obtained 
free of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html, or from the Cambridge Crystallographic Data Center, 
12 Union Road, Cambridge Cb2 1eZ, UK; Fax: (+44) 1223–336-033; or e-mail:  deposit@ccdc.cam.ac.uk. Supplementary 
data associated with this article can be found in the online version.
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